Last reviewed · How we verify
NCT06095440
A Retrospective Analysis of Outcomes in Patients with Hepatorenal Syndrome At Methodist Dallas Medical Center
trial testing Hepatorenal Syndrome outcome in Patients at Methodist Health systems in Hepatorenal Syndrome in 500 participants. Currently enrolling.
13 May 2025
Quick facts
| Lead sponsor | Methodist Health System |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 13 May 2023 |
| Primary completion | 13 May 2025 |
| Estimated completion | 13 May 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Hepatorenal Syndrome outcome in Patients at Methodist Health systems
Conditions studied
- Hepatorenal Syndrome — all drugs for Hepatorenal Syndrome →
Sponsor
Methodist Health System — full company profile →
Who can join
Adults 18 to 85, any sex, with Hepatorenal Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Hepatorenal syndrome (HRS) is a common cause of acute kidney injury (AKI) in patients with liver disease \[1\]. Increased activity and presence of vasodilators such as nitric oxide in cirrhotic patients leads to vasodilation, especially in the splanchnic circulation, resulting in hemodynamic changes that precipitate renal injury \[1\]. Patients may present with elevated serum creatinine (Cr), benign urine sediment, and low urine sodium \[1\].
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06095440
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hepatorenal Syndrome
Currently open trials in the same condition.
- NCT06525623 — Initial Resuscitation for Acute Kidney Injury in Cirrhosis · NA · recruiting
- NCT02434445 — Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients · recruiting
Other Methodist Health System trials
Trials by the same sponsor.
- NCT06698302 — Validation of COMPAT-SF Spanish Translation · recruiting
- NCT04090034 — Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors · recruiting
- NCT07486362 — Evaluation of Emergency Medicine Pharmacist Impact on Blood Culture Review Following Emergency Department Discharge · recruiting
- NCT06222424 — Emergency Medicine Pharmacist Prescriptive Authority for Resolution of Outpatient Prescription Issues · NA · completed
- NCT07492758 — Management of Extremity Injuries Registry · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06095440 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Methodist Health System
- Last refreshed: 20 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06095440.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing